MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Dulaglutide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes, built as a recombinant fusion of two modified GLP-1(7-37) analog chains attached to a human IgG4 Fc fragment (PMID 20503261). The Fc backbone blocks DPP-4 cleavage and recruits FcRn recycling, extending the half-life to about 5 days. It lowers blood glucose by stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying and reducing appetite. The label dose starts at 0.75 mg weekly, with 1.5 mg as usual maintenance and optional steps to 3.0 mg and a 4.5 mg ceiling (AWARD-11, PMID 33397768). In REWIND it cut major adverse cardiovascular events over 5.4 years (PMID 31189511). It is FDA- and EMA-approved for type 2 diabetes and cardiovascular risk reduction, but not for weight management; research-grade vials are for laboratory use only.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 0.75-4.5 mg SC once weekly
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Commercial Trulicity prefilled pens are refrigerated at 2-8 °C, may be kept at room temperature up to 30 °C for a maximum of 14 days, must be protected from light and never frozen. Research-grade lyophilized powder is stored frozen at −20 °C; once reconstituted, the solution is refrigerated at 2-8 °C and used within roughly 28 days, avoiding freeze-thaw cycles that denature the Fc-fusion protein.
Half-life: Approximately 5 days, supporting fixed once-weekly subcutaneous dosing; steady state reached in 2-4 weeks.
Route: Subcutaneous once weekly. Commercially a single-dose prefilled autoinjector pen; the vial reconstitution figures here are educational only.
Status: FDA-approved (2014) and EMA-approved for type 2 diabetes and cardiovascular risk reduction; not approved for obesity. Research vials are lab-use only.
About Dulaglutide
Dulaglutide is a once-weekly GLP-1 receptor agonist and a recombinant Fc-fusion biologic rather than a small synthetic peptide: two GLP-1 analog chains are fused to a modified human IgG4 Fc fragment, a design that resists enzymatic degradation and extends the half-life to roughly 5 days [1][2]. Clinically it is delivered as a ready-to-use, single-dose prefilled autoinjector pen (Trulicity) injected subcutaneously; the vial-plus-bacteriostatic-water figures below are an educational reconstitution reference only, not the commercial dosage form.\n\nThis guide models a 10 mg vial reconstituted with 2.0 mL of bacteriostatic water (5 mg/mL) so that label doses map cleanly onto a U-100 insulin syringe: 0.75 mg ≈ 15 units, 1.5 mg ≈ 30 units, 3.0 mg ≈ 60 units, and 4.5 mg ≈ 90 units. The approved Dulaglutide dosage begins at 0.75 mg once weekly for at least 4 weeks, then 1.5 mg as the usual maintenance dose, with optional escalation to 3.0 mg and a 4.5 mg ceiling, each increase held for at least 4 weeks to improve gastrointestinal tolerability [1][4].\n\nFrequency: Inject once weekly, on the same day each week, with or without food, rotating between the abdomen, thigh and upper arm. Dulaglutide is FDA- and EMA-approved for type 2 diabetes; the research-grade vials modeled here are presented for educational purposes only and are not intended for human use.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 10 mg dulaglutide vial; do not spray the stream directly onto the protein and never shake, because agitation foams and denatures the Fc-fusion biologic.
Gently swirl or roll the vial until the solution is completely clear; the result is a 5 mg/mL concentration (50 mcg per insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed number of units per weekly dose (0.75 mg ≈ 15 units, 1.5 mg ≈ 30 units, 3.0 mg ≈ 60 units, 4.5 mg ≈ 90 units).
Educational note: clinically dulaglutide is delivered by a prefilled single-dose autoinjector pen, not a reconstituted vial; inject subcutaneously into the abdomen, thigh or upper arm, rotating sites, and wait a few seconds before withdrawing the needle to ensure full delivery.
Interactive Dulaglutide Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1-4 — initiation | 750 mcg | 15 units (0.15 mL) |
| Weeks 5-8 — usual maintenance | 1500 mcg (1.5 mg) | 30 units (0.30 mL) |
| Weeks 9-12 — escalation (if added control needed) | 3000 mcg (3 mg) | 60 units (0.60 mL) |
| Week 13+ — maximum label dose | 4500 mcg (4.5 mg) | 90 units (0.90 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Dulaglutide, 10 mg each):
- check8-week course titrating to 1.5 mg/week ≈ about 9 mg of drug used; budget roughly 2 vials (one per 4-week reconstituted-shelf-life block)
- check12-week course titrating to 3.0 mg/week ≈ about 21 mg used; budget roughly 3 vials
- check16-week course titrating to 4.5 mg/week ≈ about 39 mg used; budget roughly 4 vials
- checkReconstituted solution is discarded after ~28 days, so leftover drug in a vial is typically wasted rather than carried over
Insulin Syringes (U-100):
- checkOnce-weekly dosing: 1 syringe per injection
- check8 weeks ≈ 8-10 syringes (including a few for reconstitution)
- check12 weeks ≈ 13-15 syringes; 16 weeks ≈ 17-20 syringes
- checkU-100 syringes measure the full dose range cleanly (15-90 units)
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- check8 weeks ≈ 2 vials reconstituted → about 4 mL water
- check12 weeks ≈ 3 vials → about 6 mL water
- check16 weeks ≈ 4 vials → about 8 mL water
- checkA single 30 mL bottle comfortably covers a full 16-week course
Alcohol Swabs:
- checkOne swab to wipe the vial stopper plus one for each injection site
- check8 weeks ≈ 16-20 swabs; 12 weeks ≈ 24-30 swabs
- check16 weeks ≈ 32-40 swabs
- checkA single box of 100 covers any of the course lengths above
Mechanism of Action (MOA)
Dulaglutide is not a small peptide but a recombinant fusion protein of roughly 63 kDa. Each molecule contains two identical chains, each made of a modified human GLP-1(7-37) analog joined through a short peptide linker to a modified human immunoglobulin G4 (IgG4) Fc fragment [2]. The GLP-1 portion shares about 90% sequence homology with native GLP-1 and carries three engineered substitutions: Ala8-to-Gly confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, while Gly22-to-Glu and Arg36-to-Gly reduce immunogenicity and improve solubility. The IgG4 Fc backbone is mutated to minimize antibody effector functions and serves two pharmacokinetic roles: its large size slows subcutaneous absorption and limits renal filtration, and its engagement of the neonatal Fc receptor (FcRn) drives receptor-mediated recycling that rescues the molecule from lysosomal degradation [2].\n\nFunctionally, dulaglutide is a full agonist at the GLP-1 receptor. It augments glucose-dependent insulin secretion from pancreatic beta-cells, suppresses inappropriate glucagon release from alpha-cells, slows gastric emptying, and acts on hypothalamic and brainstem appetite centers to reduce food intake [1][7]. Because insulinotropic action is glucose-dependent, monotherapy carries low intrinsic hypoglycemia risk.\n\nPharmacokinetically, dulaglutide is absorbed slowly after subcutaneous injection, with a median time to peak concentration (Tmax) of about 48 hours (range 24-72 hours) and a terminal elimination half-life of approximately 5 days, which supports fixed once-weekly dosing [1]. Mean absolute bioavailability is 65% for the 0.75 mg dose and 47% for the 1.5 mg dose, steady state is reached after 2-4 weeks of weekly administration, and the molecule is presumed to be catabolized into its component amino acids by general protein turnover rather than hepatic CYP metabolism, limiting classical drug-drug interactions [1].\n\nClinically the dose is titrated to balance efficacy and gastrointestinal tolerability: 0.75 mg weekly for at least 4 weeks, then 1.5 mg as standard maintenance, with optional 4-week steps to 3.0 mg and a 4.5 mg ceiling introduced after the AWARD-11 trial [1][4]. Across the AWARD program dulaglutide reduced HbA1c by roughly 1.1-1.8% and body weight by 1.5-4.6 kg in a dose-dependent fashion, and in the REWIND cardiovascular outcomes trial it lowered major adverse cardiovascular events in a broad type 2 diabetes population [4][5][6]. Note that the commercial product is a prefilled pen; the vial reconstitution scheme on this page is an educational measurement convention, and dulaglutide is not approved for weight management.
Clinical Trial Efficacy Highlights
- starAWARD-6 (Dungan et al., Lancet 2014) randomized 599 metformin-treated adults with type 2 diabetes to once-weekly dulaglutide 1.5 mg or once-daily liraglutide 1.8 mg; at 26 weeks HbA1c fell 1.42% with dulaglutide versus 1.36% with liraglutide, meeting the prespecified 0.4% non-inferiority margin with comparable tolerability [3].
- starAWARD-11 (Frias et al., Diabetes Care 2021) compared dulaglutide 1.5, 3.0 and 4.5 mg in 1,842 metformin-treated patients (baseline HbA1c 8.6%, BMI 34). At 36 weeks the 4.5 mg dose produced a 1.77% HbA1c reduction versus 1.54% with 1.5 mg, and 4.6 kg of weight loss versus 3.0 kg, establishing superiority of the higher doses [4].
- starExploratory weight analyses of AWARD-11 (Bonora et al., Diabetes Obes Metab 2021) confirmed dose-dependent weight reduction, with more patients achieving 5% and 10% body-weight loss on 3.0 and 4.5 mg than on 1.5 mg, supporting the expanded dose range as a metabolic, not purely glycemic, benefit [5].
- starREWIND (Gerstein et al., Lancet 2019) followed 9,901 adults with type 2 diabetes (about 31% with established cardiovascular disease) for a median 5.4 years. Dulaglutide 1.5 mg reduced the first major adverse cardiovascular event (cardiovascular death, non-fatal MI or non-fatal stroke) to 12.0% versus 13.4% with placebo (hazard ratio 0.88), a benefit seen in both primary- and secondary-prevention patients [6].
- starIn AWARD-3 versus metformin monotherapy, dulaglutide lowered HbA1c by roughly 0.7-0.8% from a baseline near 7.6% with 1.4-2.3 kg of weight loss, demonstrating efficacy even in early, less-advanced disease [7].
- starIn AWARD-5 versus sitagliptin, dulaglutide 1.5 mg reduced HbA1c by about 0.9-1.1% from a baseline of 8.1-8.2% and produced 2.7-3.1 kg of weight loss, with roughly 59% of 1.5 mg recipients reaching HbA1c below 7% [7].
- starThe once-weekly schedule and single-dose autoinjector pen, enabled by the roughly 5-day half-life, are associated with high adherence relative to daily injectable agents, a recognized driver of real-world glycemic outcomes [1][7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal events are the dominant adverse effects: nausea, diarrhea, vomiting, abdominal pain, dyspepsia and decreased appetite. They are dose-related, usually mild-to-moderate, concentrated during initiation and dose escalation, and tend to subside within 1-2 weeks of a stable dose; in AWARD-11 nausea occurred in roughly 13-16% and vomiting in 6-9% across doses [1][4].
- warningBoxed warning: dulaglutide causes thyroid C-cell (medullary) tumors in rodents. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); a human causal link has not been established [1].
- warningAcute pancreatitis has been reported; the label advises promptly discontinuing the drug if pancreatitis is suspected and avoiding use in patients with a history of pancreatitis [1].
- warningHypoglycemia is uncommon with monotherapy because GLP-1 action is glucose-dependent, but risk rises substantially when combined with sulfonylureas or insulin, which typically require dose reduction [1].
- warningVolume depletion from nausea, vomiting or diarrhea can precipitate acute kidney injury or worsen chronic kidney disease; patients should maintain hydration and report persistent GI losses [1].
- warningHypersensitivity and injection-site reactions can occur; serious hypersensitivity to dulaglutide or any excipient is a contraindication, and gallbladder disease and worsening diabetic retinopathy complications associated with rapid glucose improvement have also been reported [1].
- warningDulaglutide raises heart rate modestly (around 2-4 beats per minute on average) and should not be combined with other GLP-1 or incretin agents, which adds gastrointestinal and pancreatitis risk without proven benefit.
- warningRegulatory/research status: dulaglutide is FDA- and EMA-approved for type 2 diabetes and cardiovascular risk reduction in type 2 diabetes, but it is NOT approved for obesity or weight management. Research-grade vials are for laboratory use only and are not intended for human administration.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Dulaglutide dosage?expand_more
The approved Dulaglutide dosage starts at 0.75 mg by subcutaneous injection once weekly for at least 4 weeks. The usual maintenance dose is 1.5 mg once weekly. If additional glycemic control is needed, the dose can be increased in 4-week steps to 3.0 mg and then to a maximum of 4.5 mg once weekly, as established in the AWARD-11 trial. Slow titration is used mainly to reduce gastrointestinal side effects.
Is Dulaglutide FDA approved?expand_more
Yes. The FDA approved dulaglutide (Trulicity) on September 18, 2014 for adults with type 2 diabetes, and the label was later expanded to include cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors (based on REWIND), plus the higher 3.0 mg and 4.5 mg doses in 2020. It is also EMA-approved. It is NOT approved for obesity or weight management, and research-grade vials are for laboratory use only.
What is the half life of Dulaglutide and how often is it injected?expand_more
Dulaglutide has an elimination half-life of approximately 5 days, a consequence of its IgG4 Fc-fusion design, which resists DPP-4 degradation and uses neonatal Fc receptor (FcRn) recycling. This long half-life supports once-weekly subcutaneous dosing on the same day each week, with steady-state concentrations reached after about 2-4 weeks of consistent dosing.
How is Dulaglutide reconstituted and administered?expand_more
Clinically, dulaglutide is not reconstituted at all: it ships as a ready-to-use, single-dose prefilled autoinjector pen injected subcutaneously into the abdomen, thigh or upper arm. The vial-and-bacteriostatic-water figures on this page are an educational reconstitution reference. In that model, a 10 mg vial is reconstituted with 2.0 mL of bacteriostatic water to give 5 mg/mL (50 mcg per unit on a U-100 syringe), so 0.75 mg is 15 units, 1.5 mg is 30 units, 3.0 mg is 60 units and 4.5 mg is 90 units.
Can Dulaglutide be stacked with other GLP-1 drugs like semaglutide or tirzepatide?expand_more
No. Dulaglutide should not be combined with semaglutide, tirzepatide, liraglutide, exenatide or any other GLP-1 or incretin agent. They act on overlapping receptors, so stacking sharply increases gastrointestinal toxicity, pancreatitis risk and, with sulfonylureas or insulin, hypoglycemia risk, without added proven benefit. Clinicians switch between agents rather than overlapping them, and any change should be supervised by a prescriber.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Dulaglutide, plus the universal dosing calculator.
Academic References & Study Citations
Trulicity (dulaglutide) injection, for subcutaneous use — full FDA prescribing information, Eli Lilly and Company (revised 2020). Dosing, pharmacokinetics, boxed warning and adverse reactions. View Scientific Paper →
Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287-296. View Scientific Paper →
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349-1357. View Scientific Paper →
Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021;44(3):765-773. View Scientific Paper →
Bonora E, Frias JP, Tinahones FJ, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes Obes Metab. 2021;23(10):2242-2250. View Scientific Paper →
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. View Scientific Paper →
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2015 (PMC4665063). Mechanism and AWARD-3/AWARD-5 summary. View Scientific Paper →
Eli Lilly and Company. FDA approves additional doses of Trulicity (dulaglutide) 3.0 mg and 4.5 mg for the treatment of type 2 diabetes. Press release, September 2020. View Scientific Paper →